Lincoln National Corp Nymox Pharmaceutical Corp Transaction History

Lincoln National Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 04, 2023	BUY	$0.19 - $0.49 $2,130 - $5,495	11,215 New	11,215 $2,000
Q4 2021 Jan 26, 2022	BUY	$0.95 - $2.1 $9,799 - $21,661	10,315 New	10,315 $13,000
Q1 2020 Apr 24, 2020	SELL	$1.69 - $3.88 $16,900 - $38,800	-10,000 Closed	0 $0
Q4 2019 Feb 07, 2020	BUY	$1.73 - $2.42 $17,300 - $24,200	10,000 New	10,000 $22,000

150K

Ticker NYMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,265,000
Market Cap $42.9M
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...

Get notified when there are updates to the investment portfolio of Lincoln National Corp, based on Form 13F filings with the SEC.

Stay updated on Lincoln National Corp with notifications on news.